The Administrators of Tulane Educational Fund, doing business as Tulane University, received a $185,513 Project Grant (R21) from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) to develop an enterotoxigenic Escherichia coli (ETEC) multivalent subunit vaccine using outer membrane vesicles. The project aims to establish protective anti-ETEC immunity in the gastrointestinal tract by evaluating the ability of OMV-adjuvanted vaccines targeting ETEC colonization factors and toxins to induce antibodies that can neutralize toxins and prevent bacterial colonization. The project will be conducted over a 2-year period from March 1, 2025 to February 28, 2027 at Tulane University in Louisiana.
Generated 3/18/25, 3:31 AM